Ken Griffin Applied Genetic Technologies Corp Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.29 - $0.89 $122,875 - $377,101	423,709 New	423,709 $115,000
Q1 2022 May 16, 2022	SELL	$1.07 - $2.71 $3,825 - $9,688	-3,575 Reduced 6.67%	50,041 $53,000
Q4 2021 Feb 14, 2022	SELL	$1.87 - $2.91 $94,535 - $147,112	-50,554 Reduced 48.53%	53,616 $101,000
Q3 2021 Nov 15, 2021	SELL	$3.01 - $4.12 $58,667 - $80,302	-19,491 Reduced 15.76%	104,170 $313,000
Q2 2021 Aug 16, 2021	BUY	$3.62 - $5.23 $125,027 - $180,633	34,538 Added 38.75%	123,661 $483,000
Q1 2021 May 17, 2021	BUY	$3.94 - $8.19 $351,144 - $729,917	89,123 New	89,123 $452,000
Q1 2018 May 11, 2018	SELL	$3.65 - $5.2 $60,345 - $85,971	-16,533 Closed	0 $0
Q4 2017 Feb 09, 2018	SELL	$3.4 - $4.15 $84,105 - $102,658	-24,737 Reduced 59.94%	16,533 $60,000
Q3 2017 Nov 09, 2017	BUY	$3.55 - $5.25 $146,508 - $216,667	41,270	41,270 $163,000

Ticker AGTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,632,200
Description
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Pha...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.